Retatrutide is a triple GIP/GLP-1/glucagon agonist targeting insulin secretion and energy metabolism
BPC-157 / TB-500 is a precision co-lyophilized research blend combining two well-characterized peptides in a fixed 1:1 ratio, supplied exclusively for laboratory and preclinical research applications
While GHK-Cu is generally well-tolerated in topical research, certain contraindications or precautions should be considered, especially for systemic research or in specific populations: Systemic Research: For systemic applications, GHK-Cu is generally not recommended for subjects who are pregnant, breastfeeding, have active cancer, or suffer from Wilsons disease (a condition involving copper accumulation)
The copper peptides for hair guide covers application specifics
In clinical trials with semaglutide oral tablets for T2DM, 14 (0.5%) of patients developed anti-semaglutide antibodies
Biochemical changes showing early deficiency 3